Genelux Corporation
NASDAQ:GNLXBiotechnology
Healthcare
$2.24 +2.63%
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
52W Low $2.29High $8.54
Volume 0.80M
Average 0.19M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$25.27M
FY 2025 · Annual
Investing Cash Flow
$12.14M
FY 2025 · Annual
Financing Cash Flow
$9.89M
FY 2025 · Annual
-65.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$32.1M
+ D&A$244.0K
+ Stock-Based Comp$5.9M
+ Deferred Tax$0
- Working Capital-$1.0M
+ Other Non-Cash$1.8M
= Operating Cash Flow-$25.3M
- Capex-$1.1M
= Free Cash Flow-$26.4M
Analysis
FY2025 free cash flow is -$26.4M. FCF conversion is 82.0% of net income. Operating cash flow was -$25.3M, with capex of -$1.1M. The largest bridge item is Stock-Based Comp at $5.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
Does GNLX generate free cash flow?
Genelux Corporation (GNLX) generated -$26.37M of free cash flow in fiscal 2025.
How much operating cash flow does GNLX produce?
Operating cash flow was -$25.27M, before capital expenditures of $1.10M.
Continue the stock analysis
Jump to another research area for this company.